Analysis of the Mechanism of Action and Therapeutic Efficacy of Semaglutide in the Treatment of Type 2 Diabetes Mellitus
DOI:
https://doi.org/10.61173/aq4yjk08Keywords:
Type 2 diabetes mellitus, semaglutide, blood sugarAbstract
How to control Type 2 Diabetes Mellitus (T2DM) has been one of the most important current health issues which should be given priority to. Against this background, Semaglutide has created a new breakthrough point for this predicament: while protecting the cardiovascular system and liver, it controls the patient's blood glucose level through two pathways. This article focuses on analyzing the mechanism of action of semaglutide and explores its current shortcomings. As a glucagon-like peptide-1 (GLP- 1) receptor agonist, semaglutide achieves both blood sugar lowering and weight loss via a multifaceted mechanism. In the field of T2DM treatment, large-scale clinical trials have confirmed that semaglutide not only has a strong hypoglycemic effect, but also lowers risk of hypoglycemia and clearly protect the cardiovascular, and has become the first-line choice for patients with cardiovascular diseases or high-risk factors. Future research should focus on a more comprehensive evaluation of the drug's safety, while also emphasizing its clinical benefits.
References
peutic effect, this drug can achieve a significant reduction Investigation, 2022, 13(1): 6-13. in weight through multiple mechanisms such as central [2] Niemuth N J, Klaper R D. Low-dose metformin exposure appetite suppression, delayed gastric emptying and energy causes changes in expression of endocrine disruption-associated
expenditure regulation. It is particularly worth mentioning genes[J]. Aquatic Toxicology, 2018, 195: 33-40. that some patients have achieved improvements in meta- [3] Yang X D, Yang Y Y. Clinical pharmacokinetics of bolic indicators such as blood lipids and blood sugar while semaglutide: a systematic review[J]. Drug Design, Development
losing weight, and the benefits far exceed those of other and Therapy, 2024, 18: 2555-2570. common weight loss drugs. At present, the combination [4] Zheng Z, Gao L Y. I am not a miracle drug: a dialogue on
of semaglutide and metformin has become increasingly semaglutide[J]. University Chemistry, 2025, 40(1): 297-302. mature. Multiple randomized controlled trials indicate that [5] Papakonstantinou I, Tsioufis K, Katsi V. Spotlight on the concomitant use of the two agents potentiates semaglu- mechanism of action of semaglutide[J]. Current Issues in
tide's efficacy while posing no additional safety concerns Molecular Biology, 2024, 46(12): 14514-14541. [12]. However, semaglutide still has problems such as [6] Rakhat Y, Wang L, Han W, et al. Oral semaglutide under weight rebound after discontinuation and gastrointestinal human protocols and doses regulates food intake, body weight, discomfort in the early stage of use. These issues indicate and glycemia in diet-induced obese mice[J]. Nutrients, 2023, that semaglutide is not a so-called all-powerful "miracle 15(17): 3765. drug", and clinical use requires more caution. [7] Deng Z, Zheng D, Son J, et al. Effect of weight-neutral treatment with semaglutide or tirzepatide on β-cell identity in
db/db mice[J]. Acta Physiologica, 2026, 242(1): e70141. 5. Conclusion [8] Tian M Y, Yang J Q, Hu J C, et al. Semaglutide The advent of semaglutide represents a major advance administration protects cardiomyocytes in db/db mice via in the therapeutic field of T2DM. As a standalone glu- energetic improvement and mitochondrial quality control[J].
cose-lowering agent, it has delivered remarkable effi- Acta Pharmacologica Sinica, 2025, 46(5): 1250-1261. cacy: it acts through multiple parallel glucose-lowering [9] Goldenberg R M, Steen O. Semaglutide: review and place in pathways, concurrently regulating pancreatic β-cells and therapy for adults with type 2 diabetes[J]. Canadian Journal of
α-cells to maintain glycemic control, and possesses nu- Diabetes, 2019, 43(2): 136-145. merous advantages that were unavailable in previous first- [10] Rodbard H W, Rosenstock J, Canani L H, et al. Oral line antidiabetic medications, such as cardioprotective and semaglutide versus empagliflozin in patients with type 2 diabetes hepatoprotective effects, thereby providing a novel ther- uncontrolled on metformin: the PIONEER 2 trial[J]. Diabetes
apeutic option for a large number of patients. Addition- Care, 2019, 42(12): 2272-2281. ally, semaglutide can be used in combination with other [11] Nieto L M, Martinez J, Narvaez S I, et al. Glucagon-like agents to enhance overall therapeutic efficacy, and future peptide-1 receptor agonists use does not increase the risk for research can prioritize combination therapy with multiple acute pancreatitis and is associated with lower complications in agents, with the aim of advancing the development from patients with type 2 diabetes who develop acute pancreatitis: a single-target to multi-target medications. multicenter analysis[J]. American Journal of Gastroenterology,
Nevertheless, all medications have dual effects, and sema- 2026, 121(2): 424-431. glutide still has potential associations with adverse events [12] Li J, Li K, Liu Z, et al. Efficacy and safety of semaglutide such as pancreatitis. Every relevant clinical case must not combined with metformin in treating T2DM with overweight be overlooked, the potential adverse effects of semaglu- or obesity: a systematic review and meta-analysis[J]. American
tide still warrant careful attention.While further exploring Journal of Translational Research, 2024, 16(8): 3545-3556.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
